The extended collaboration comes as the Japanese company intends to take a lead candidate into preclinical development, within the area of inflammation.
The lead candidate was discovered using BioInvent’s n-CoDeR antibody library.
Under the extended agreement BioInvent will do stable cell line and process development and clinical manufacturing of the therapeutic candidate.
The partner will fund all development work performed by BioInvent.
BioInvent will also continue to receive milestone payments and royalties upon successful development and commercialization.
Earlier the agreement was signed in December 2008.
Under the terms of that agreement, the two companies collaborated to develop of an antibody based drug sourced from Bioinvent’s n-CoDeR antibody library.
BioInvent CEO Svein Mathisen said that this collaboration has been very successful and they are happy to further strengthen and progress their partnership.
"The structure of this deal exemplifies BioInvents strength as a partner, not only providing a quality antibody discovery capability, but also support and expertise in product development and manufacture. BioInvent is a strong partner throughout the development process for therapeutic antibody drugs," Mathisen said.